Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment

Gut

Volumn 46, Issue 1, 2000, Pages 121-126

  Leuschner, M ^a   Dietrich, C F ^a   You, T ^a   Seidl, C ^b   Raedle, J ^a   Herrmann, G ^c   Ackermann, H ^a   Leuschner, U ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Institute of Transfusion Medicine and Immunohematology of the RCBDS   (Germany)

^c Senckenbergisches Institute of Pathology   (Germany)

Author keywords

Anti p53 autoantibodies; Full response to ursodeoxycholic acid; HLA typing; Incomplete responders; Primary biliary cirrhosis; Prognostic indexes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; PROTEIN P53; SMOOTH MUSCLE ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HLA TYPING; HUMAN; IMMUNE STATUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0034125417     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.1.121     Document Type: Article

References (35)

1. 1 David R, Kurtz W, Strohm WD, et al. Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten. Eine Pilotstudie [abstract]. Z Gastroenterol 1985;23:420.
2. 2 Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-74.
3. 3 Heathcote EJL, Cauch-Dudek K, Walker V, et al. The Canadian multicentre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
4. 4 Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
5. 5 Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66.
6. 6 Leuschner U, Güldütuna S, Imhof M, et al. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994;21: 624-33.
7. 7 Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113: 884-90.
8. 8 Ben Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10-15.
9. 9 Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35:260-5.
10. 10 Goodman ZD, McNally PR, Davis DR, et al. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232-42.
11. 11 Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997;26:22-6.
12. 12 Güldütuna S, You T, Kurtz W, et al. High performance liquid chromatographic determination of free and conjugated bile acids in serum, liver biopsies, bile, gastric juice and feces by fluorescence labeling. Clin Chim Acta 1993;214: 195-207.
13. 13 Terasaki PI, McClelland. Microdroplet assay for human serum lymphotoxins. Nature 1964;204:998-1000.
14. 14 Bein G, Gläser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplication. Tissue Antigens 1992;39: 68-73.
15. 15 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleids Acids Res 1988;16:1215.
16. 16 Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch 1978;379:103-12.
17. 17 Bengtsson BO, Thomson G. Measuring the strength of association between HLA antigens and diseases. Tissue Antigens 1981;18:356-63.
18. 18 Svejgaard A, Jersild C, Staub Nielsen L, et al. HLA Antigens and disease: statistical and genetical considerations. Tissue Antigens 1974;4:95-105.
19. 19 Jorgensen RA, Dickson ER, Hofmann AF, et al. Characterization of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-8.
20. 20 Bounand A-M, Heathcote EJ, Lindor KD, et al. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999;29:39-43.
21. 21 Angelopoulou K, Diamandis EP, Sutherland DJA, et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58:480-7.
22. 22 Livni N, Eid A, Ilan Y, et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995;75:2420-6.
23. 23 Klöppel G, Kirchhof M, Berg PA. Natural course of PBC. I. A morphological, clinical and serological analysis of 103 cases. Liver 1982;2:141-51.
24. 24 Klein R, Pointer H, Zilly W, et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10 years. Liver 1997;17:119-28.
25. 25 Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
26. 26 Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996;23:1148-53.
27. 27 Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985;89:1084-91.
28. 28 Güldütuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993;104:1736-44.
29. 29 Güldütuna S, Deisinger B, Weiss A, et al. Ursodeoxycholic acid stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim Biophys Acta 1997;1326:265-74.
30. 30 Beuers U, Throckmorton DC, Anderson MS, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996;110:1553-63.
31. 31 Krähenbühl S, Fischer S, Talos C, et al. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 1994;20:1595-601.
32. 32 Krähenbühl S, Talos C, Fischer S, et al. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 1994;19:471-9.
33. 33 Ljubuncic P, Fuhrman B, Oiknine J, et al. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxydation in cultured macrophages. Gut 1996;39:475-8.
34. 34 Setchell KDR, Rodriguez CMP, Clerici C. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997;112:226-35.
35. 35 Ricci P, Hofmann AF, Hagey LR, et al. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci 1998;43:1292-5.